GKOS · Glaukos Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $150.57M | - | $133.54M | $124.12M | $106.66M | - | $96.67M | $95.69M | $85.62M | - |
| Cost of Revenue | $33.34M | - | $28.83M | $26.90M | $24.32M | - | $22.58M | $22.55M | $20.26M | - |
| Gross Profit | $117.23M | - | $104.71M | $97.22M | $82.35M | - | $74.09M | $73.14M | $65.36M | - |
| R&D | $44.15M | - | $38.07M | $36.54M | $32.35M | - | $34.75M | $34.43M | $30.73M | - |
| SG&A | $92.94M | - | $83.00M | $83.38M | $70.67M | - | $64.00M | $66.19M | $61.98M | - |
| Total Operating Expenses | $137.09M | - | $121.07M | $119.91M | $103.03M | - | $98.75M | $103.11M | $104.43M | - |
| D&A | $11.80M | - | - | - | $8.91M | - | - | - | $2.69M | - |
| Operating Income | ($19.86M) | - | ($16.36M) | ($22.69M) | ($20.68M) | - | ($24.66M) | ($29.97M) | ($39.07M) | - |
| Interest Expense | $1.13M | - | $1.18M | $1.15M | $3.45M | - | $1.66M | $3.35M | $3.45M | - |
| Income Tax | $484.0K | - | $234.0K | $248.0K | $326.0K | - | $177.0K | $331.0K | $377.0K | - |
| Net Income | ($19.78M) | - | ($16.23M) | ($19.66M) | ($18.15M) | - | ($21.41M) | ($50.55M) | ($40.84M) | - |
| EPS - Basic | ($0.34) | - | ($0.28) | ($0.34) | ($0.32) | - | ($0.39) | ($1.00) | ($0.82) | - |
| EPS - Diluted | ($0.34) | - | ($0.28) | ($0.34) | ($0.32) | - | ($0.39) | ($1.00) | ($0.82) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $104.25M | $90.81M | $98.25M | $100.81M | $114.25M | $169.63M | $100.14M | $68.08M | $42.49M | $93.47M |
| Accounts Receivable | $119.69M | $108.61M | $98.68M | $82.98M | $71.53M | $60.74M | $56.41M | $51.22M | $46.55M | $39.85M |
| Inventory | $62.38M | $63.56M | $63.86M | $64.62M | $59.46M | $57.68M | $59.90M | $56.48M | $50.19M | $41.99M |
| Accounts Payable | $19.15M | $24.62M | $19.88M | $13.68M | $15.82M | $13.03M | $11.10M | $11.56M | $12.75M | $13.44M |
| Current Assets | $485.75M | $474.98M | $454.77M | $436.06M | $444.54M | $449.79M | $397.28M | $383.78M | $388.61M | $395.46M |
| Total Assets | $893.33M | $893.49M | $999.38M | $986.96M | $966.18M | $974.76M | $926.54M | $919.67M | $933.34M | $940.41M |
| Current Liabilities | $89.42M | $101.28M | $87.52M | $79.14M | $68.53M | $75.13M | $71.68M | $70.08M | $72.24M | $74.01M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $222.40M | $237.33M | $229.84M | $221.85M | $202.22M | $207.82M | $258.03M | $254.52M | $482.61M | $478.65M |
| Stockholders' Equity | $670.93M | $656.15M | $769.54M | $765.11M | $763.96M | $766.93M | $668.51M | $665.16M | $450.73M | $461.77M |
| Retained Earnings | ($952.91M) | ($933.13M) | ($799.47M) | ($783.24M) | ($763.59M) | ($745.44M) | ($711.86M) | ($690.45M) | ($639.90M) | ($599.07M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($12.53M) | - | - | - | ($18.52M) | - | - | - | ($33.87M) | - |
| Investing Cash Flow | $10.50M | - | - | - | ($36.95M) | - | - | - | ($29.38M) | - |
| Financing Cash Flow | $15.77M | - | - | - | $1.95M | - | - | - | $13.17M | - |
| CapEx | $3.96M | - | - | - | $1.94M | - | - | - | $968.0K | - |
| Free Cash Flow | ($16.48M) | - | - | - | ($20.46M) | - | - | - | ($34.84M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 77.9% | - | 78.4% | 78.3% | 77.2% | - | 76.6% | 76.4% | 76.3% | - |
| Operating margin | -13.2% | - | -12.3% | -18.3% | -19.4% | - | -25.5% | -31.3% | -45.6% | - |
| EBITDA margin | -5.4% | - | - | - | -11.0% | - | - | - | -42.5% | - |
| Net margin | -13.1% | - | -12.2% | -15.8% | -17.0% | - | -22.1% | -52.8% | -47.7% | - |
| Free cash flow margin | -10.9% | - | - | - | -19.2% | - | - | - | -40.7% | - |
| FCF / Net income | 0.83 | - | - | - | 1.13 | - | - | - | 0.85 | - |
| R&D / Revenue | 29.3% | - | 28.5% | 29.4% | 30.3% | - | 35.9% | 36.0% | 35.9% | - |
| SG&A / Revenue | 61.7% | - | 62.2% | 67.2% | 66.3% | - | 66.2% | 69.2% | 72.4% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -2.2% | - | -1.6% | -2.0% | -1.9% | - | -2.3% | -5.5% | -4.4% | - |
| Return on equity | -2.9% | - | -2.1% | -2.6% | -2.4% | - | -3.2% | -7.6% | -9.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.43 | 4.69 | 5.20 | 5.51 | 6.49 | 5.99 | 5.54 | 5.48 | 5.38 | 5.34 |
| Quick ratio | 4.73 | 4.06 | 4.47 | 4.69 | 5.62 | 5.22 | 4.71 | 4.67 | 4.68 | 4.78 |
| Cash ratio | 1.17 | 0.90 | 1.12 | 1.27 | 1.67 | 2.26 | 1.40 | 0.97 | 0.59 | 1.26 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -17.6x | - | -13.9x | -19.7x | -6.0x | - | -14.8x | -8.9x | -11.3x | - |
| Equity multiplier | 1.33 | 1.36 | 1.30 | 1.29 | 1.26 | 1.27 | 1.39 | 1.38 | 2.07 | 2.04 |
| Liabilities / Assets | 0.25 | 0.27 | 0.23 | 0.22 | 0.21 | 0.21 | 0.28 | 0.28 | 0.52 | 0.51 |
| Efficiency | ||||||||||
| Asset turnover | 0.17 | - | 0.13 | 0.13 | 0.11 | - | 0.10 | 0.10 | 0.09 | - |
| Inventory turnover | 0.53 | - | 0.45 | 0.42 | 0.41 | - | 0.38 | 0.40 | 0.40 | - |
| Days sales outstanding | 290d | - | 270d | 244d | 245d | - | 213d | 195d | 198d | - |
| Days inventory outstanding | 683d | - | 809d | 877d | 893d | - | 968d | 914d | 904d | - |
| Days payable outstanding | 210d | - | 252d | 186d | 238d | - | 179d | 187d | 230d | - |
| Cash conversion cycle | 763d | - | 827d | 935d | 900d | - | 1002d | 922d | 873d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 9.3x | - | 6.1x | 7.7x | 7.3x | - | 10.7x | 9.0x | 10.4x | - |
| P / S | 41.5x | - | 35.1x | 47.6x | 52.3x | - | 74.2x | 62.7x | 54.6x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 41.2% | - | 38.1% | 29.7% | 24.6% | - | 23.9% | 19.0% | 15.9% | - |
| Revenue CAGR (3y) | 26.8% | - | 23.3% | 19.5% | 16.4% | - | 9.0% | 7.0% | 8.0% | - |
| Revenue CAGR (5y) | 17.2% | - | 15.5% | 31.5% | 14.0% | - | 10.6% | 10.3% | 9.6% | - |
| Gross profit growth (YoY) | 42.4% | - | 41.3% | 32.9% | 26.0% | - | 24.4% | 21.3% | 17.1% | - |
| Operating income growth (YoY) | 4.0% | - | 33.6% | 24.3% | 47.1% | - | 12.0% | -3.1% | -18.4% | - |
| Net income growth (YoY) | -9.0% | - | 24.2% | 61.1% | 55.6% | - | 29.7% | -54.0% | -17.9% | - |
| EPS growth (YoY) | -6.3% | - | 28.2% | 66.0% | 61.0% | - | 38.1% | -47.1% | -13.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 19.4% | - | - | - | 41.3% | - | - | - | 7.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -12.2% | -14.4% | 15.1% | 15.0% | 69.5% | 66.1% | 40.0% | 36.1% | -11.4% | -12.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$507.44M totalDevelopment And Commercialization Of Ophthalmic Therapies$507.44M · 100.0%
Product / service
$375.04M totalGlaucoma$298.59M · 79.6%
Corneal Health$76.45M · 20.4%
Geographic
$507.44M totalUS$375.04M · 73.9%
Non Us$132.40M · 26.1%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing GLAUKOS Corp against the 5 most active filers in the same SIC group.